Summary sheet
The project covers Orion’s Research & Development activities in the period 2009 up to and including 2012. The focus of these activities is for projects that fall within Orion’s core areas of pharmaceutical expertise.
The project covers Orion’s Research & Development activities in the period 2009 up to and including 2012. The focus of these activities is for projects that fall within Orion’s core areas of pharmaceutical expertise.
The project involves activities that will be carried out within existing R&D facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA is therefore not required by the EIA Directive 85/337/EEC, amended by Directive 97/11/EC. The promoter’s R&D facilities comply with relevant EU and environmental legislation.
The R&D activities are mostly carried out by internal staff. The promoter carries out competitive enquiries among potential suppliers for goods and services. These procedures, which are typical for the industry, are in the best interests of the project and satisfactory to the Bank.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications